Collaboration with GlaxoSmithKline to target NMT in malaria
A red blood cell infected with the malaria parasite.
勛圖厙 and GSK have signed a collaborative agreement to work on the development of antimalarial agents targeting N-myristoyltransferase (NMT).
The project will see researchers in the Tate Group working in collaboration with scientists at GSK's , which specialises in drug discovery for neglected tropical diseases, to optimise novel malaria parasite NMT inhibitors and explore their mode of action and selectivity.
Our group previously demonstrated that NMT is a in malaria, and we also developed the high-throughput screening which GSK used to discover the current inhibitor series.
Article text (excluding photos or graphics) © 勛圖厙.
Photos and graphics subject to third party copyright used with permission or © 勛圖厙.
Reporter
Charlotte Sutherell
Department of Chemistry